Personalized mRNA cancer vaccine sparks lasting response in pancreatic cancer trial

A small Phase 1 trial of personalized mRNA vaccines given after surgical removal of operable pancreatic cancer and standard chemo shows that after nine doses, several patients mounted a durable T-cell–driven immune response. Six years of follow-up indicate that some responders remain alive and cancer-free, suggesting potential long-term benefit, though the results are early and come from a limited group as researchers move to a larger Phase 2 study.